Zoetis (ZTS) Liabilities and Shareholders Equity (2012 - 2026)
Zoetis (ZTS) posted quarterly Liabilities and Shareholders Equity of $15.2 billion for Q1 2026, up 7.49% year-over-year from $14.1 billion in Q1 2025, and down 2.17% quarter-over-quarter from $15.5 billion in Q4 2025.
Zoetis (ZTS) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $15.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 7.49% year-over-year to $15.2 billion; the TTM figure through Mar 2026 stood at $60.3 billion (up 6.09% YoY), while the FY2025 annual figure was $15.5 billion, up 9.08% from the prior year.
- Liabilities and Shareholders Equity retreated to $15.2 billion in Q1 2026 per ZTS's latest filing, from $15.5 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $15.5 billion in Q4 2025 and bottomed at $13.7 billion in Q3 2022.
- Historically, Liabilities and Shareholders Equity has averaged $14.3 billion across 5 years, with a median of $14.2 billion in 2024.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity decreased 4.28% — and 2025, when it rose 9.08%.
- Zoetis' Liabilities and Shareholders Equity stood at $14.9 billion in 2022, then retreated by 4.28% to $14.3 billion in 2023, then slipped by 0.6% to $14.2 billion in 2024, then gained by 9.08% to $15.5 billion in 2025, then fell by 2.17% to $15.2 billion in 2026.
- Business Quant data shows ZTS's Liabilities and Shareholders Equity at $15.2 billion in Q1 2026, $15.5 billion in Q4 2025, and $15.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 4.39 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.08 Bn |
| Mar 31, 2026 | 15.15 Bn |
| Dec 31, 2025 | 15.49 Bn |
| Sep 30, 2025 | 15.16 Bn |
| Jun 30, 2025 | 14.48 Bn |
| Mar 31, 2025 | 14.10 Bn |
| Dec 31, 2024 | 14.20 Bn |
| Sep 30, 2024 | 14.36 Bn |
| Jun 30, 2024 | 14.17 Bn |
| Mar 31, 2024 | 14.35 Bn |
| Dec 31, 2023 | 14.29 Bn |
| Sep 30, 2023 | 14.11 Bn |
| Jun 30, 2023 | 13.75 Bn |
| Mar 31, 2023 | 13.75 Bn |
| Dec 31, 2022 | 14.93 Bn |
| Sep 30, 2022 | 13.67 Bn |
| Jun 30, 2022 | 13.77 Bn |
| Mar 31, 2022 | 13.86 Bn |
| Dec 31, 2021 | 13.90 Bn |
| Sep 30, 2021 | 13.71 Bn |